151 related articles for article (PubMed ID: 37300636)
1. Developing an Artificial Intelligence-Guided Signal Detection in the Food and Drug Administration Adverse Event Reporting System (FAERS): A Proof-of-Concept Study Using Galcanezumab and Simulated Data.
Al-Azzawi F; Mahmoud I; Haguinet F; Bate A; Sessa M
Drug Saf; 2023 Aug; 46(8):743-751. PubMed ID: 37300636
[TBL] [Abstract][Full Text] [Related]
2. Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System.
Battini V; Carnovale C; Clementi E; Sessa M
Expert Opin Drug Saf; 2023; 22(11):1105-1112. PubMed ID: 37293948
[TBL] [Abstract][Full Text] [Related]
3. A characterization and disproportionality analysis of medication error related adverse events reported to the FAERS database.
Carnovale C; Mazhar F; Pozzi M; Gentili M; Clementi E; Radice S
Expert Opin Drug Saf; 2018 Dec; 17(12):1161-1169. PubMed ID: 30451017
[TBL] [Abstract][Full Text] [Related]
4. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
5. Optimizing Signal Management in a Vaccine Adverse Event Reporting System: A Proof-of-Concept with COVID-19 Vaccines Using Signs, Symptoms, and Natural Language Processing.
Dong G; Bate A; Haguinet F; Westman G; Dürlich L; Hviid A; Sessa M
Drug Saf; 2024 Feb; 47(2):173-182. PubMed ID: 38062261
[TBL] [Abstract][Full Text] [Related]
6. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
[TBL] [Abstract][Full Text] [Related]
7. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
8. New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database.
Sessa M; Andersen M
BioDrugs; 2021 Mar; 35(2):215-227. PubMed ID: 33609278
[TBL] [Abstract][Full Text] [Related]
9. Post-marketing safety surveillance of erenumab: new insight from Eudravigilance.
Liang D; Sessa M
Expert Opin Drug Saf; 2022 Sep; 21(9):1205-1210. PubMed ID: 35236231
[TBL] [Abstract][Full Text] [Related]
10. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
Michel C; Scosyrev E; Petrin M; Schmouder R
Clin Drug Investig; 2017 May; 37(5):415-422. PubMed ID: 28224371
[TBL] [Abstract][Full Text] [Related]
11. Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.
Berbain T; Pariente A; Miremont-Salamé G; Grandvuillemin A; Micallef J; Chouchana L; Benkebil M; Théophile H;
Drug Saf; 2020 Mar; 43(3):243-253. PubMed ID: 31974775
[TBL] [Abstract][Full Text] [Related]
12. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
[TBL] [Abstract][Full Text] [Related]
13. Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.
Martin GL; Jouganous J; Savidan R; Bellec A; Goehrs C; Benkebil M; Miremont G; Micallef J; Salvo F; Pariente A; Létinier L;
Drug Saf; 2022 May; 45(5):535-548. PubMed ID: 35579816
[TBL] [Abstract][Full Text] [Related]
14. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
15. Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA.
Fukazawa C; Hinomura Y; Kaneko M; Narukawa M
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1402-1408. PubMed ID: 30324671
[TBL] [Abstract][Full Text] [Related]
16. An experimental investigation of masking in the US FDA adverse event reporting system database.
Wang HW; Hochberg AM; Pearson RK; Hauben M
Drug Saf; 2010 Dec; 33(12):1117-33. PubMed ID: 21077702
[TBL] [Abstract][Full Text] [Related]
17. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
de Bie S; Ferrajolo C; Straus SM; Verhamme KM; Bonhoeffer J; Wong IC; Sturkenboom MC;
PLoS One; 2015; 10(6):e0130399. PubMed ID: 26090678
[TBL] [Abstract][Full Text] [Related]
18. Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions.
Lu Z; Suzuki A; Wang D
BMC Med Res Methodol; 2023 Mar; 23(1):71. PubMed ID: 36973693
[TBL] [Abstract][Full Text] [Related]
19. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.
Caster O; Aoki Y; Gattepaille LM; Grundmark B
Drug Saf; 2020 May; 43(5):479-487. PubMed ID: 32008183
[TBL] [Abstract][Full Text] [Related]
20. Changing paradigms in detecting rare adverse drug reactions: from disproportionality analysis, old and new, to machine learning.
Arku D; Yousef C; Abraham I
Expert Opin Drug Saf; 2022 Oct; 21(10):1235-1238. PubMed ID: 36181369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
